Haemophilus influenzae type b conjugate vaccines

Immunology

Volumn 113, Issue 2, 2004, Pages 163-174

  Kelly, Dominic F ^a   Moxon, E Richard ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Conjugate; Haemophilus influenzae; Immunological memory; Polysaccharide; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLYRIBOSYL RIBITOL PHOSPHATE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BACTERIAL INFECTION; COVALENT BOND; DRUG PROTEIN BINDING; HAEMOPHILUS INFLUENZAE TYPE B; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INDUSTRIALIZATION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; POLYSACCHARIDES, BACTERIAL; TREATMENT FAILURE; VACCINES, CONJUGATE;

EID: 4744374650     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01971.x     Document Type: Review

References (120)

1. Anderson P, Johnston RB Jr, Smith DH. Human serum activities against Hemophilus influenzae, type b. J Clin Invest 1972; 51:31.
2. Weller PF, Smith AL, Smith DH, Anderson P. Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J Infect Dis 1978; 138:427.
3. Pittman M. Variation and type specificity in the bacterial species Haemophilus influenzae. J Exp Med 1931; 53:471.
4. Moxon ER, Kroll JS. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol 1990; 150:65.
5. Swift AJ, Moxon ER, Zwahlen A, Winkelstein JA. Complement-mediated serum activities against genetically defined capsular transformants of Haemophilus influenzae. Microb Pathog 1991; 10:261.
6. Winkelstein JA, Moxon ER. The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 1992; 165 (Suppl. 1):S62.
7. Alexander H, Heidleberger M, Leidy G. The protective or curative element in type B H. influenzae rabbit serum. Yale J Biol Med 1944; 16:425.
8. Anderson P, Smith DH, Ingram DL, Wilkins J, Wehrle PF, Howie VM. Antibody of polyribophate of Haemophilus influenzae type b in infants and children: effect of immunization with polyribophosphate. J Infect Dis 1977; 136 (Suppl.):S57.
9. Schneerson R, Robbins JB. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075: K 100: H5. N Engl J Med 1975; 292:1093.
10. Barbour ML, Booy R, Crook DW, Griffiths H, Chapel HM, Moxon ER, Mayon-White D. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 1993; 12:478.
11. Hall DB, Lum MK, Knutson LR, Heyward WL, Ward JI. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in southwestern Alaska. Am J Epidemiol 1987; 126:1190.
12. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993; 69:225.
13. Bennet JV, Platonov AE, Slack MPE, Mala P, Burton AH, Robertson SE. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era. a global review of incidence, age distributions, and case-fatality rates. In: Vaccines and Biologicals. Geneva: WHO, 2002.
14. Bijlmer HA, van Alphen L, Greenwood BM et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. J Infect Dis 1990; 161:1210.
15. Parke JC Jr, Schneerson R, Robbins JB, Schlesselman JJ. Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J Infect Dis 1977; 136 (Suppl.):S51.
16. Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children. a double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60:730.
17. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P. Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae, type b. Pediatrics 1973; 52:637.
18. Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74:857.
19. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655.
20. Fairhurst RM, Wang CX, Sieling PA, Modlin RL, Braun J. CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria. Immunol Today 1998; 19:257.
21. Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987; 111:22.
22. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine 1998; 16:1396.
23. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997; 77:488.
24. Hougs L, Juul L, Ditzel HJ, Heilmann C, Svejgaard A, Barington T. The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. J Immunol 1999; 162:224.
25. Anderson P, Ingram DL, Pichichero ME, Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J 2000; 19:589.
26. Norden CW, Michaels RH, Melish M. Effect of previous infection on antibody response of children to vaccination with capsular polysaccharide of Haemophilus influenzae Type b. J Infect Dis 1975; 132:69.
27. Trollfors B, Lagergard T, Claesson BA, Thornberg E, Martinell J, Schneerson R. Characterization of the serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b in children with invasive infections. J Infect Dis 1992; 166:1335.
28. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140:690.
29. Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol 2002; 169:6149.
30. Goebel WF. Studies on antibacterial immunity induced by artificial antigens. II. Immunity to experimental pneumococcal infection with antigens containing saccharides of synthetic origin. J Exp Med 1940; 72:33.
31. Avery O, Goebel WT. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50:522.
32. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152:361.
33. Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983; 40:245.
34. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 1983; 39:233.
35. Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest 1985; 76:52.
36. Granoff DM, Boies EG, Munson RS Jr. Immunogenicity of Haemophilus influenzae type b polysaccharide - diphtheria toxoid conjugate vaccine in adults. J Pediatr 1984; 105:22.
37. Anderson P, Pichichero ME, Insel RA. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b. J Pediatr 1985; 107:346.
38. Anderson P, Pichichero M, Edwards K, Porch CR, Insel R. Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. J Pediatr 1987; 111:644.
39. Kayhty H, Eskola J, Peltola H, Saarinen L, Makela PH. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J Infect Dis 1992; 165 (Suppl. 1):S165.
40. Anderson P, Pichichero M, Insel R, Farsad P, Santosham M. Capsular antigens noncovalently or covalently associated with protein as vaccines to Haemophilus influenzae type b: comparison in two-year-old children. J Infect Dis 1985; 152:634.
41. Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ. Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Infect Immun 1999; 67:789.
42. Siber GR. Pneumococcal disease. prospects for a new generation of vaccines. Science 1994; 265:1385.
43. Arpin C, Dechanet J, Van Kooten C et al. Generation of memory B cells and plasma cells in vitro. Science 1995; 268:720.
44. Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997; 159:2652.
45. Symonds J, Bone M, Turner A, Javaid A. Penetration of ofloxacin into bronchial secretions. Drugs 1987; 34 (Suppl. 1):33.
46. Kamboj KK, King CL, Greenspan NS, Kirchner HL, Schreiber JR. Immunization with Haemophilus influenzae type b-CRM (197) conjugate vaccine elicits a mixed Thl and Th2 CD (4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J Infect Dis 2001; 184:931.
47. Leiva LE, Butler B, Hempe J, Ortigas AP, Sorensen RU. Up-regulation of CD40 ligand and induction of a Th2 response in children immunized with pneumococcal polysaccharide vaccines. Clin Diagn Lab Immunol 2001; 8:233.
48. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 2004; 172:2431.
49. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177:1112.
50. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171:4969.
51. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199.
52. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523.
53. Heath PT, Booy R, Azzopardi HJ et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334.
54. Goldblatt D, Miller E, McCloskey N, Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. Br Med J 1998; 316:1570.
55. Campos M, Godson DL. The effectiveness and limitations of immune memory: understanding protective immune responses. Int J Parasitol 2003; 33:655.
56. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002; 14:523.
57. McVernon J, Johnson PD, Pollard AJ, Slack MP, Moxon ER. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003; 88:379.
58. Lucas AH, Granoff DM. Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr Infect Dis J 2001; 20:235.
59. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188:1679.
60. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 1996; 14:1239.
61. McVernon J, Mitchison NA, Moxon ER. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 2004; 4:40.
62. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol 2000; 30:1214.
63. Granoff DM, Anderson EL, Osterholm MT et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187.
64. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184.
65. Kayhty H, Eskola J, Peltola H, Ronnberg PR, Kela E, Karanko V, Saarinen L. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145:223.
66. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992; 267:1489.
67. Capeding MR, Nohynek H, Pascual LG, Kayhty H, Sombrero LT, Eskola J, Ruutu P. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hyg 1996; 55:516.
68. Wenger JD, Booy R, Heath P, Moxon ER. Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS eds. New Generation Vaccines, 2nd edn. New York: Marcel Dekker, Inc, 1997:489.
69. Makela PH, Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines 2002; 1:399.
70. Kelly DF, Moxon ER. Is Haemophilus Influenzae Type b Disease Finished. In: Pollard AJ, McCracken GH, Finn A, eds. Hot Topics in Infection and Immunity in Children. New York: Kluwer Academic/Plenum Publishers, 2004:221.
71. Englund JA, Glezen WP. Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 2003; 21:3455.
72. Kurikka S, Olander RM, Eskola J, Kayhty H. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. Pediatr Infect Dis J 1996; 15:530.
73. Nohynek H, Gustafsson L, Capeding MR, Kayhty H, Olander RM, Pascualk L, Ruutu P. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr Infect Dis J 1999; 18:25.
74. Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Furer E, Que JU, Hasler T, Cryz SJ Jr. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 2000; 78:364.
75. Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson EL. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 1994; 272:1116.
76. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21:3406.
77. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11 (Suppl. 1):S46.
78. Lieberman JM, Greenberg DP, Wong VK, Partridge S, Chang SJ, Chiu CY, Ward JI. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995; 126:198.
79. Granoff DM, Holmes SJ, Osterholm MT et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168:663.
80. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 1999; 354:2063.
81. Eskola J, Peltola H, Takala AK et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317:717.
82. Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349:1191.
83. Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MP. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 1992; 340:847.
84. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics 1993; 92:272.
85. Eskola J, Takala A, Kayhty H, Peltola H, Makela PH. Experience in Finland with Haemophilus influenzae type b vaccines. Vaccine 1991; 9 (Suppl.):S14.
86. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86:396.
87. Talan DA, Moran GJ, Pinner RW. Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States 1987-97. Ann Emerg Med 1999; 34:109.
88. Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, Makela PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164:982.
89. Murphy TV, White KE, Pastor P, Gabriel L, Medley F, Granoff DM, Osterholm MT. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 1993; 269:246.
90. Galil K, Singleton R, Levine OS et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179:101.
91. Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22:397.
92. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of 'natural' and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973; 7:103.
93. Makela PH, Peltola H, Kayhty H et al. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136 (Suppl.):S43.
94. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
95. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171:93.
96. Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993; 122:517.
97. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998; 177:1758.
98. Pichichero ME, Insel RA. Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule. J Allergy Clin Immunol 1983; 72:481.
99. Kauppi M, Eskola J, Kayhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 1995; 14:286.
100. Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, Romero-Steiner S. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000; 182:1553.
101. Rushdy A, Ramsay M, Heath PT, Azzopardi HJ, Slack MP. Infant Hib vaccination and herd immunity. J Pediatr 1999; 134:253.
102. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481.
103. HPA. Laboratory reports of Haemophilus influenzae type B infection by age group and quarter England and Wales 1990-2003. http://www.hpa.org.uk/ infections/topics_az/haemophilus_influenzae/data.htm. 2003.
104. Kroll JS, Moxon ER. Capsulation in distantly related strains of Haemophilus influenzae type b: genetic drift and gene transfer at the capsulation locus. J Bacteriol 1990; 172:1374.
105. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003; 6:55.
106. Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997; 94:271.
107. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521.
108. Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349:1197.
109. Heath PT, Booy R, Griffiths H et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973.
110. Breukels MA, Spanjaard L, Sanders LA, Rijkers GT. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants. Clin Infect Dis 2001: 32, 1700.
111. Holmes SJ, Granoff DM. The biology of Haemophilus influenzae type b vaccination failure. J Infect Dis 1992; 165 (Suppl. 1):S121.
112. Makela PH, Kayhty H, Leino T, Auranen K, Peltola H, Ekstrom N, Eskola J. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22:287.
113. Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses. Curr Med Res Opin 2001; 17:197.
114. Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 2001; 184:1293.
115. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EA. Return of Haemophilus influenzae type b infections. Lancet 2003; 361:1563.
116. Heath PT, Ramsay ME. Haemophilus influenzae type b vaccine - booster campaign. Br Med J 2003; 326:1158.
117. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302.
118. WHO. The Global Programme for Vaccines and Immunisation (GPV) The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec, Vol. 73 1998: p 64.
119. Booy R. Getting Hib vaccine to those who need it. Lancet 1998; 351:1446.
120. Lee JW. Haemophilus influenzae in Asia. Pediatr Infect Dis J 1998; 17:S92.